• Profile
Close

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: A retrospective analysis

OncoTargets and Therapy May 04, 2018

Wang LL, et al. - In a real-life setting, the efficacy of combination icotinib and chemotherapy was compared to that of icotinib or chemotherapy alone in untreated non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)-sensitive mutations. Additionally, the curative impact of different treatments on different genetic mutations (EGFR 19 exon deletion and L858R mutation) was analyzed in this retrospective analysis. Improved progression free survival and overall survival were achieved with combination icotinib and chemotherapy in patients with untreated NSCLC harboring sensitive EGFR mutations, particularly in those who harbored the EGFR exon 19 deletion.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay